These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 31420757

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Valbenazine in the treatment of tardive dyskinesia.
    Witek N, Comella C.
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L.
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM, Nicewonder JA.
    J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN, Aggarwal S, Yonan C.
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [Abstract] [Full Text] [Related]

  • 10. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM.
    CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
    Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K.
    Tremor Other Hyperkinet Mov (N Y); 2024 Aug; 14():13. PubMed ID: 38497033
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Current treatment of tardive dyskinesia.
    Margolius A, Fernandez HH.
    Parkinsonism Relat Disord; 2019 Feb; 59():155-160. PubMed ID: 30591350
    [Abstract] [Full Text] [Related]

  • 16. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
    Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV.
    N Engl J Med; 2017 Jun 29; 376(26):2503-2506. PubMed ID: 28489481
    [No Abstract] [Full Text] [Related]

  • 17. Valbenazine (Ingrezza) for tardive dyskinesia.
    Med Lett Drugs Ther; 2017 May 22; 59(1521):83-84. PubMed ID: 28520698
    [No Abstract] [Full Text] [Related]

  • 18. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
    Kim AP, Baker DE, Levien TL.
    Consult Pharm; 2018 Apr 01; 33(4):201-209. PubMed ID: 29609698
    [Abstract] [Full Text] [Related]

  • 19. Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
    Citrome LL.
    J Clin Psychiatry; 2020 Jan 28; 81(2):. PubMed ID: 31995679
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Tardive Dyskinesia.
    Bashir HH, Jankovic J.
    Neurol Clin; 2020 May 28; 38(2):379-396. PubMed ID: 32279716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.